<DOC>
	<DOC>NCT02395640</DOC>
	<brief_summary>This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.</brief_summary>
	<brief_title>The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer</brief_title>
	<detailed_description>This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Major inclusion criteria had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1 an Eastern Cooperative Oncology Group performance status of 0 to 2 adequate renal, hepatic, and hematologic function Major exclusion criteria previous chemotherapy or radiotherapy (unless in the adjuvant setting) uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer accumulated dose of Epirubicin exceeds 300mg/m2 HER2 positive and willing to use trastuzumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>